The quest for population-level cancer recurrence data; current deficiencies and targets for improvement.

J Surg Oncol

Department of Surgery, University of Chicago, Chicago, Illinois; Division of Research and Optimal Patient Care, American College of Surgeons, Chicago, Illinois.

Published: May 2015

Background: Cancer recurrence is a critical outcome in cancer care. However, population-level recurrence information is currently unavailable. Tumor registries provide an opportunity to generate this information, but require major reform. Our objectives were to (1) determine causes for variability in collection of recurrence, and (2) identify targets for intervention.

Methods: On-site interviews and observations of tumor registry follow-up procedures were conducted at Commission on Cancer (CoC) accredited hospitals. Information regarding registry resources (caseload, staffing, chart availability), follow-up methods and perceived causes for difficulty in obtaining recurrence information was obtained.

Results: Seven NCI/academic, 5 comprehensive community and 2 community centers agreed to participate. Hospitals were inconsistent in their investigation of cancer recurrence, resulting in underreporting of rates of recurrence. Hospital characteristics, registry staffing, staff qualifications and medical chart access influenced follow-up practices. Coding standards and definitions for recurrence were suboptimal, resulting in hospital variability of recurrence reporting. Finally, inability to identify cases lost to follow-up in collected data prevents accurate analysis of recurrence rates.

Conclusion: Tumor registries collect varying degrees of recurrence information and provide the underpinnings to capture population-level cancer recurrence data. Targets for intervention are listed, and provide a roadmap to obtain this critical information in cancer care.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.23883DOI Listing

Publication Analysis

Top Keywords

cancer recurrence
16
recurrence
12
population-level cancer
8
recurrence data
8
cancer care
8
tumor registries
8
cancer
7
quest population-level
4
data current
4
current deficiencies
4

Similar Publications

CBA-1205 is a novel humanized antibody targeting delta-like 1 homolog (DLK1) that enhances antibody-dependent cellular cytotoxicity activity. DLK1 overexpression has been reported in various cancer types, such as hepatocellular carcinoma and neuroblastoma. CBA-1205 demonstrates potent antitumor activity in multiple tumor models, making it a potential treatment option for DLK1-expressing cancers.

View Article and Find Full Text PDF

Clinical application of the KangDuo-Surgical Robot-01 in distal gastrectomy for gastric cancer.

Updates Surg

January 2025

Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, 150, Haping Road, Nangang District, Harbin, 150076, Heilongjiang, China.

This study aimed to explore the safety, feasibility, and efficacy of using KangDuo-Surgical Robot-01 (KD-SR-01) for distal gastrectomy in patients with gastric cancer. We prospectively enrolled patients undergoing KD-SR-01 assisted distal gastrectomy at our center from September 2023 to December 2023. Data on baseline characteristics, perioperative details, and short-term follow-up were collected prospectively.

View Article and Find Full Text PDF

Ovarian cancer is a deadly gynecological disease with frequent recurrence. Current treatments for patients include platinum-based therapy regimens with PARP inhibitors specific for HR-deficient high-grade serous ovarian cancers (HGSOCs). Despite initial effectiveness, patients inevitably develop disease progression as tumor cells acquire resistance.

View Article and Find Full Text PDF

Introduction: Small cell neuroendocrine carcinoma of the urinary tract (SCNEC-URO) has an inferior prognosis compared to conventional urothelial carcinoma (UC). Here, we evaluate the predictors and patterns of relapse after surgery.

Materials And Methods: We identified a definitive-surgery cohort (n = 224) from an institutional database of patients with cT1-T4NxM0 SCNEC-URO treated in 1985-2021.

View Article and Find Full Text PDF

Background: The optimal extent of lymph node resection for early-stage non-small cell lung cancer (NSCLC) remains a topic of debate in the medical community. We aimed to assess the surgical and prognostic outcomes based on the extent of mediastinal lymph node dissection (MLND) for resectable clinical stage IA NSCLC.

Methods: From 2016 to 2018, 1,166 patients with clinical stage IA NSCLC who underwent lobectomy or segmentectomy with complete mediastinal lymph node dissection (C-MLND) or selective mediastinal lymph node dissection (S-MLND) at five hospitals were enrolled.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!